Early-onset gastrointestinal cancer patterns in Navarre: incidence, tumour features and patient survival outcomes
Background Despite growing awareness of the rising incidence and particular features of early-onset gastrointestinal cancer (EOGIC), evidence from Spain remains limited. The purpose of this study was to compare EOGIC with average-onset gastrointestinal cancer (AOGIC) in Navarre, by analysing incidence trends, clinicopathological features and patients' relative survival (RS). Materials and methods Patients with EOGIC (18-49 years) and AOGIC (≥50 years) diagnosed with colorectal, gastroesophageal, pancreatic and hepatobiliary cancer between 2015 and 2025 were considered. Incidence trends were evaluated using age-standardised incidence rates and annual percentage changes (APCs); survival outcomes were estimated through RS and relative excess risk (RER). Results A total of 5053 patients were included, of whom 5.38% were EOGIC. Although the incidence of AOGIC declined (APC = −2.80, P < 0.05), the incidence of EOGIC remained stable (APC = 1.77, P = 0.547). Patients with EOGIC presented with more advanced tumour stages ( P < 0.05), and those with early-onset gastroesophageal and pancreatic ductal adenocarcinoma (EOGEA and EOPDAC) were enriched with poorly differentiated tumours ( P < 0.05). Diffuse histology was more represented in EOGEA ( P < 0.05). Patients with EOGIC presented similar 3-year RS ( P = 0.911) and a comparable RER to patients with AOGIC. In contrast, by tumour stage, patients with EOGIC with locally advanced or metastatic tumours exhibited better 3-year RS ( P < 0.05) and lower stage-adjusted RER (RER 0.738, P < 0.05). Conclusions The incidence of EOGIC in Navarre remained stable, whereas AOGIC declined. Patients with EOGIC were mostly females, presented with more aggressive tumours and had lower stage-adjusted mortality risk.
Authors
- I. Hernández-García
- Mónica Enguita‐Germán (ORCID: https://orcid.org/0000-0002-2890-1252)
- Ana E. Huerta (ORCID: https://orcid.org/0000-0003-1911-5310)
- Virginia Arrazubi (ORCID: https://orcid.org/0000-0002-1431-2780)
- Hugo Arasanz (ORCID: https://orcid.org/0000-0001-6838-6702)
- David Gómez (ORCID: https://orcid.org/0000-0002-7265-0251)
- Javier Suárez (ORCID: https://orcid.org/0000-0002-2446-7663)
- Ibone Labiano (ORCID: https://orcid.org/0000-0001-8901-9653)
- C. Miranda
- I. Cáseda (ORCID: https://orcid.org/0009-0001-7371-9310)
- B. Agirre (ORCID: https://orcid.org/0009-0007-2843-5216)
- A. Lecumberri (ORCID: https://orcid.org/0000-0002-8598-2992)
- R. Termini
- T. Prieto
- E. Mata
- M. Alsina
- C. Zazpe
- R. Vera
- M.D. Marquinez (ORCID: https://orcid.org/0000-0002-8004-0410)
Institutions
- Complejo Hospitalario de Navarra (ES)
- Navarre Institute of Health Research (ES)
- Navarrabiomed (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2026-08-24
- DOI
- https://doi.org/10.1016/j.esmorw.2026.100761
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación Científica Asociación Española Contra el Cáncer
- Departamento de Salud, Gobierno de Navarra
- Instituto de Salud Carlos III